Cambridge, Massachusetts
Pfizer is strengthening its oncology research pipeline through a new program launched under its strategic collaboration with Flagship Pioneering, focused on developing T-cell receptor (TCR) bispecific immune medicines for metastatic prostate cancer.
As part of the initiative, Flagship-founded Repertoire Immune Medicines will apply its proprietary DECODE™ immune mapping platform to identify and optimize novel TCR bispecific candidates designed to precisely engage the immune system against prostate cancer. The goal is to advance an early optimized lead with the potential for durable disease control and improved tolerability.
The program is being led by Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, which works closely with Pfizer to align cutting-edge bioplatform innovation with clinical development and translational expertise. This marks the eighth research program initiated under the Flagship–Pfizer strategic partnership established in 2023.
Repertoire’s DECODE™ platform enables a comprehensive analysis of immune synapse interactions, uncovering previously uncharacterized antigen targets and immune pathways. When combined with immune medicine engineering capabilities, the platform supports the development of next-generation, T-cell–directed therapies.
Metastatic prostate cancer continues to present significant treatment challenges, with many patients developing resistance to standard therapies. TCR bispecific immunotherapies are emerging as a promising modality to overcome immune escape mechanisms and enhance treatment durability.
The collaboration reflects Pfizer’s broader strategy to expand its oncology pipeline through partnerships that integrate advanced immune science, precision medicine approaches, and scalable drug development platforms.
By
